In January 2026, Uplift Investors announced the formation of Orion Legal MSO with Dudley DeBosier Injury Lawyers. It barely made the trade press.

It should have been above the fold.

Warburg Pincus is actively scanning plaintiffs' firms. So is Littlejohn. So is MidOcean. Private equity has discovered what it does to every fragmented, cash-generative professional-services industry sooner or later: it rolls it up. Personal injury — thousands of small firms, high gross margins, recurring referral flow, predictable case-value distributions — checks every box.

If you own a PI firm and you think this is someone else's story, you have about 18 months of denial left.

Why PI looks like candy to capital

The pitch deck writes itself:

  • Fragmentation. The top 100 PI firms still represent a small fraction of the $50B+ PI industry. Most local markets have dozens of 1–20-lawyer firms.
  • Cash generation. A mature PI firm produces 25–40% operating margins without much capital intensity.
  • Platform opportunity. Regional consolidation plus shared operations (intake, marketing, medical review, settlement ops) equals immediate EBITDA expansion.
  • AI tailwind. The same technology that's compressing the cost of operating a PI practice makes a centralized MSO a force multiplier, not a call center.

When PE underwriters model "add 40% to EBITDA in year one by centralizing intake and marketing," they aren't wrong. They're doing to PI what they already did to vet clinics, dental practices, dermatology, audiology, and about 20 other professional-services verticals.

What happens when they arrive in your market

It goes in three waves.

Wave one: the anchor buy. A PE sponsor writes a big check to a local market leader — the firm you've been losing associates to for five years. Purchase price is 6–9x EBITDA plus rollover equity for the partners. The firm becomes the MSO platform.

Wave two: the tuck-ins. The platform starts offering roll-in deals to adjacent firms: "Join us. Keep your brand. Get our intake ops, our AI, our media buying, our relationships." Tuck-ins close at 3–5x EBITDA plus equity. The partners of those firms — tired, running businesses they didn't sign up to run — take the deal.

Wave three: the squeeze. The MSO now has outsized media budget, a faster intake funnel, and institutional capital behind it. Non-affiliated firms in the market start bleeding cases. The principals of those firms get the call next: sell now at 2–3x, or wait until you're distressed.

You already know which firms in your market are looking for the anchor call.

The counter-position nobody's talking about

Here's what the PE thesis gets wrong:

The leverage they're buying from operations, you can build yourself. For less.

A PE-backed MSO's moat is scale advantage in intake ops, marketing spend, and internal systems. Every one of those is now buyable off-the-shelf or buildable with AI:

  • Intake ops → AI-powered intake that runs 24/7, qualifies cases, routes referrals. Available to any firm for under $1K/month.
  • Media spend → if you're measured on cost per signed case (not cost per click), you can out-efficiency a generic MSO because you know your niche better than they do.
  • Internal systems → AI-assisted medical review, demand-package generation, case triage — same tooling, no PE carry, no integration tax.

The only durable advantage PE brings is capital to wait out a bad year. Everything else is commoditizing into software you can subscribe to.

The independent PI firm that deploys AI leverage deliberately is the firm that out-runs the MSO model, not the one that gets rolled up into it.

The honest choice

Three paths. Pick one now.

  1. Sell now, before the squeeze. Valuations are rich. Partners get meaningful liquidity. Downside: you're employed in your own firm for the next 3–5 years on someone else's terms.
  2. Build the independent moat. Invest in AI operations now so your firm produces MSO-level efficiency on its own. Downside: you have to actually do the work.
  3. Wait and negotiate from weakness. The path most firms will take by default. Downside: every quarter you wait, your leverage shrinks.

The one thing that's off the table is running the practice the way you ran it in 2022.

What PIMP covers next

Over the next few weeks, the Field Manual goes deep on the independent-firm playbook: which AI investments actually move EBITDA, how to audit your intake funnel for leakage before a PE firm sees it, what your firm needs to look like to command a premium multiple when the call comes.

If you're thinking about path 2 and you want a second pair of eyes on what your moat actually looks like today, we're running free SEO + operations audits for PI firms through Press Check Marketing. Three slots a week. Thirty minutes. No deck.

Request yours here.

Stack wins.